Y-134

Y-134, also written Y134 and referred to in some work as an analog of raloxifene, is a synthetic selective estrogen receptor modulator (SERM) created by chemically modifying the approved SERM raloxifene ^[1][3]. It retains raloxifene's benzothiophene core, and, as a member of the SERM class, it is designed to act as an estrogen antagonist in some tissues, such as the breast, while behaving as an estrogen agonist in others, such as bone; this tissue-selective behavior is the hallmark of SERMs and the reason drugs like raloxifene are used to protect bone and reduce breast cancer risk.

What has drawn scientific attention to Y-134 is a second, less expected property. Research had shown that raloxifene is not only an estrogen receptor ligand but also a ligand for the aryl hydrocarbon receptor (AhR), through which it can induce cell death in estrogen-receptor-negative cancer cells ^[2]. In a structure-activity study of seven raloxifene analogs, Y-134 was identified as a standout that strongly activates AhR-mediated activity and triggers apoptosis in triple-negative breast cancer cells, positioning it as a promising lead for further anti-cancer development ^[1].

Y-134 is strictly a preclinical research compound. It has been studied only in cell and animal models, has never entered human clinical trials, and is not approved as a medicine anywhere; it is available only as a research chemical, and its long-term safety in people is unknown. Its identity as a distinct, more selective raloxifene derivative has been confirmed in independent work, where even small structural differences between raloxifene and Y-134 produced markedly different biological effects ^[3].

Y-134 is a preclinical research compound with no human trials, so its real-world safety is unmapped. Judging by its raloxifene lineage, the class risks worth flagging are venous blood clots, hot flashes, and leg cramps; raloxifene carries a boxed warning for thromboembolism, and there is no reason to assume an analog is exempt. On the plus side, zebrafish embryo testing found Y-134 notably less toxic than raloxifene itself. It is not approved anywhere and is sold strictly as a research chemical, not for human use. Anyone pregnant or with a clotting history should stay well clear, and the total absence of long-term human data is the honest headline here.

Y-134, also written Y134, emerged from the Cancer Research Laboratory in the Department of Environmental and Molecular Toxicology at Oregon State University, in the group led by Siva Kumar Kolluri. Its origin traces to earlier work by the same laboratory, which in 2014 reported that the selective estrogen receptor modulator raloxifene is also a direct ligand of the aryl hydrocarbon receptor (AhR) and induces AhR-dependent apoptosis in estrogen-receptor-negative cancer cells (O'Donnell et al., Cell Death & Disease, 2014).

Building on that discovery, Jang and colleagues performed a structure-activity study of seven raloxifene analogs to define the structural features required for AhR-mediated transcriptional activity and apoptosis, work published in the journal Biology in December 2017. From this screen they singled out Y-134 as an analog that activates AhR-mediated transcription and induces apoptosis in MDA-MB-231 triple-negative breast cancer cells and in hepatoma cells. The investigators proposed Y-134 as a promising candidate for further optimization as an AhR-targeted anti-cancer agent; it has remained a preclinical research compound with no reported human testing.

Within the small community studying the aryl hydrocarbon receptor as a cancer target, Y-134 is regarded as an elegant proof of concept: a modest tweak to a familiar, well-characterized drug that sharpened its most interesting off-target behavior. Researchers find it appealing because it retains the tissue-selective estrogen receptor profile of the raloxifene scaffold while more effectively engaging the AhR to push triple-negative breast cancer cells, a notoriously hard-to-treat subtype, into programmed cell death.

Its dependence on the AhR is clean and well documented; silencing the receptor sharply reduced Y-134-induced apoptosis, which makes it a useful and selective tool for dissecting AhR biology. Adding to its appeal, zebrafish embryo toxicity testing indicated a significantly better safety margin than the parent compound raloxifene. That said, its reputation rests entirely on laboratory and animal studies; Y-134 has never been evaluated in humans, so its real-world efficacy, dosing, and safety are genuinely unknown and it should be understood strictly as a research chemical.